CPHA Canvax

This document provides NACI's recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age. 

Additional Authors: Oliver Baclic, Marina Salvadori, Leanne  Coward, Eva Wong, Michael Tunis, Sarah Wilson, Robyn Harrison and Shelly Deeks

Rating See Comments Ratings


Vaccine Safety and Development,Vaccine Safety,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Management,Allocation and Distribution Vaccine Safety and Development
Vaccine Safety
Monitoring and Surveillance
Outbreaks and Pandemics
Program Planning and Delivery
Program Delivery and Evaluation
Vaccine Management
Allocation and Distribution


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.